A
Alcista
Alcista · 25%GSK
$39.86
Precio del escenario
$47.870
+1.656 (+3.46%)Al cierre
Loading chart…
- Máximo
- 47.980
- Apertura
- 46.630
- Precio medio ponderado por volumen
- 47.47
- Volumen
- 7.09M
- Capitalización
- 78.79B
- Mínimo
- 46.550
- Importe
- 336.45M
- EV/EBITDA, TTM
- 8.17
GSK plc is a United Kingdom-based biopharma company. The Company is focused on the science of the immune system and advanced technologies, investing in four core therapeutic areas-respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its segments include Commercial Operations and Research and Development. Its specialty medicines prevent and treat diseases, from asthma, cancer and HIV to autoimmune diseases like lupus. General medicines include inhalers for asthma and chronic obstructive pulmonary disease (COPD) to antibiotics. It also owns ozureprubart, a long-acting anti-immunoglobulin E (IgE) monoclonal antibody and HS235, a potential molecule for the treatment of pulmonary hypertension (PH). Its oncology portfolio also includes Zidesamtinib (NVL-520), neladalkib (NVL-655), and NVL-330. Its products include Anoro Ellipta, Apretude, Arexvy, Bexsero, Blenrep, Blujepa, Boostrix, Cervarix, Dovato, Efimosfermin, among others.
Análisis de IA of GSK plc (GSK)
MantenerGSK is currently not a strong buy due to its low RSI of 25.177, indicating oversold conditions, and a forward P/E of 9.7656, which suggests the stock may be undervalued. However, the recent 5-day change of -1.13% and a 20-day change of -3.39% indicate a downward trend, which could signal further price drops. The main risk is the current price being significantly below the 200-day SMA of 52.37, suggesting a potential for continued weakness in the near term.
Recomendaciones de analistas (4)
-19.11% Potencial de caída
Mantener
1 Comprar
3 Mantener
0 Vender
Actual: 47.87
Mínimo
20.15
Promedio
38.72
Máximo
55.60
Berenberg
Comprar
—
2026-09-15
Berenberg
2026-09-15
Precio objetivo
—
Comprar
HSBC
Mantener
—
2026-09-10
HSBC
2026-09-10
Precio objetivo
—
Mantener
RBC Capital
Sector Perform
—
2026-09-08
RBC Capital
2026-09-08
Precio objetivo
—
Sector Perform
Morgan Stanley
Infraponderar
—
2026-08-25
Morgan Stanley
2026-08-25
Precio objetivo
—
Infraponderar
Deutsche Bank
Mantener
—
2026-07-30
Deutsche Bank
2026-07-30
Precio objetivo
—
Mantener
Métricas de valoración
El PER previsto actual de GSK plc (GSK) es 9.77, frente a su media de 5 años de 10.16.
Escenarios de precio de Alphio AI para GSK
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con GSK en cartera
Cronología de eventos
Noticias
8.010-14FoolThree Companies with Sustainable Dividend Growth
6.010-09CNBCLatest Wall Street Ratings Overview
8.510-08PRnewswireGSK Partners with Viola Davis to Launch Shingles Awareness Campaign
8.510-02CNBCNovartis Signs $7.8 Billion Deal with Chinese Biotech Abogen
2.010-02NewsfilterNovartis Enters $7.8 Billion Licensing Deal with Chinese Biotech
Preguntas frecuentes sobre GSK, respondidas por Alphio AI
GSK plc is a United Kingdom-based biopharma company. The Company is focused on the science of the immune system and advanced technologies, investing in four core therapeutic areas-respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its segments include Commercial Operations and Research and Development. Its specialty medicines prevent and treat diseases, from asthma, cancer and HIV to autoimmune diseases like lupus. General medicines include inhalers for asthma and chronic obstructive pulmonary disease (COPD) to antibiotics. It also owns ozureprubart, a long-acting anti-immunoglobulin E (IgE) monoclonal antibody and HS235, a potential molecule for the treatment of pulmonary hypertension (PH). Its oncology portfolio also includes Zidesamtinib (NVL-520), neladalkib (NVL-655), and NVL-330. Its products include Anoro Ellipta, Apretude, Arexvy, Bexsero, Blenrep, Blujepa, Boostrix, Cervarix, Dovato, Efimosfermin, among others. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
GSK is currently not a strong buy due to its low RSI of 25.177, indicating oversold conditions, and a forward P/E of 9.7656, which suggests the stock may be undervalued. However, the recent 5-day change of -1.13% and a 20-day change of -3.39% indicate a downward trend, which could signal further price drops. The main risk is the current price being significantly below the 200-day SMA of 52.37, suggesting a potential for continued weakness in the near term.
4 analysts cover GSK: 1 rate it Buy, 3 Hold and 0 Sell. The average price target is 38.72.
Comunidad
Más ↗
$MAR $GSK $HWM Many people enter the crypto space chasing quick profits, but real, consistent success is built on knowledge, discipline, and the right guidance. That’s where having a reliable mentor makes all the difference. Craig has played a key role in helping me understand the markets with more clarity and confidence. His approach to trading goes beyond signals, it’s about building structure, managing risk, and staying focused on long-term growth. With his guidance and his YouTube videos, I’ve been able to make smarter decisions, avoid emotional trading, and stay consistent even in volatile conditions. The shift in mindset alone has been a game changer.
Mostrar más
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.